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Summary
Posterior reversible encephalopathy syndrome (PRES) is a clinical/radiological syndrome 
characterized by symptoms that can include seizure, headache, impaired vision and hypertension, 
and can be confirmed by magnetic resonance imaging. Numerous reports have emerged that 
describe PRES in cancer patients. The list of medications linked to PRES can include traditional 
cytotoxic chemotherapeutics (e.g., cisplatin, cyclophosphamide, and high-dose corticosteroids), 
newer agents that target the vascular endothelial growth factor pathway (e.g., bevacizumab, 
sunitinib, and pazopanib), and supportive care mediations (e.g., granulocyte colony stimulating 
factors and erythropoietin). We report, for the first time, a case of PRES that is secondary to 
treatment with enzalutamide, a potent androgen receptor antagonist used in the treatment of 
metastatic castration-resistant prostate cancer. Enzalutamide is approved for the treatment of both 
docetaxel-pretreated and chemotherapy-naïve metastatic castration-resistant prostate cancer. 
Enzalutamide has been previously linked to the increased risk of seizures. Clinicians should be 
aware that, in rare cases, patients treated with enzalutamide could potentially be at risk for PRES. 
If symptoms suggestive of PRES arise in patients receiving enzalutamide, the drug should be 
discontinued immediately and the diagnostic process should be initiated.
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Posterior reversible encephalopathy syndrome (PRES, also known as reversible posterior 
leukoencephalopathy syndrome) is a rare but serious clinical/radiological syndrome. Patients 
may present with clinical symptoms that include confusion, altered consciousness, seizures, 
headache, impaired vision, and acute hypertension.[1,2] However, because many of the 
clinical signs and symptoms of PRES are nonspecific, diagnosis is confirmed by 
neuroimaging findings. Magnetic resonance imaging (MRI) typically demonstrates bilateral 
hyperintensity on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images, 
which is indicative of subcortical edema in parietal and occipital lobes.[2,3] Fortunately, 
PRES is reversible in the majority of patients who are diagnosed and appropriately treated, 
with clinical signs and symptoms dissipating and MRI findings normalizing within days to 
weeks.[1-4]
Enzalutamide is an oral, next-generation anti-androgen that inhibits binding of androgen 
ligands to the androgen receptor (AR) and prevents both AR translocation into the nucleus 
and DNA binding and co-activator recruitment at the transcription complex.[5] After the 
phase III AFFIRM trial demonstrated a positive efficacy and safety profile for enzalutamide, 
it was approved by the U.S. FDA in August 2012 for the treatment of docetaxel-pretreated 
metastatic castration-resistant prostate cancer (mCRPC).[6] The AFFIRM study revealed 
that rates of fatigue, diarrhea, hot flashes, musculoskeletal pain, headache, and seizure were 
higher in the enzalutamide-treated patients. In September 2014, the FDA expanded the 
approval for enzalutamide to include treatment of chemotherapy-naïve mCRPC based on 
results from the phase III PREVAIL trial.[7] In the PREVAIL study, rates of fatigue, 
arthralgia, back pain, hot flushes, and hypertension were higher in the enzalutamide-treated 
patients. Here we report, for the first time, a case of enzalutamide-induced PRES.
Case Report
A 76-year-old man was started on androgen deprivation with leuprolide acetate for diffuse 
bone metastases two years prior to this admission. His past medical history was significant 
for chronic renal insufficiency (baseline creatinine of 2.0 mg/dl) and a history of multiple 
urinary tract infections, but no history of hypertension, headache, seizure, or stroke. After 17 
months on androgen deprivation therapy, the serum prostate-specific antigen (PSA) level 
increased from 1.6 ng/ml to 8.7 mg/ml. Due to the development of mCRPC, the patient was 
initially treated with sipuleucil-T, and then with enzalutamide (160 mg once daily). After 
four months of treatment with enzalutamide, the PSA level decreased from 14.9 ng/ml to 0.7 
ng/ml.
After four months of enzalutamide treatment, the patient presented to the emergency 
department with complaints of altered mental status that worsened during preceding two-
week period. He presented with confusion and experienced word-finding difficulty. The 
patient’s medication regimen included enzalutamide, calcium, vitamin D, and hydrocodone-
acetaminophen (taken as needed). Physical examination revealed elevated blood pressure of 
188/97 mm Hg. The patient exhibited moderate to severe cognitive linguistic deficits, 
including impaired memory skills, reasoning skills, auditory comprehension, executive 
Crona and Whang Page 2













functioning, and written expression. A brain MRI revealed significantly abnormal T2/
FLAIR signals, which is indicative of diffuse vasogenic edema (more severe in the left 
hemisphere) involving the occipital, temporal, parietal, and frontal lobes. There was also 
involvement of the corpus callosum, and a 7-mm left-to-right midline shift was observed. 
Multiple foci of microhemorrhage were observed throughout the brain; however, there was 
no evidence of acute infarct or extra-axial fluid collection. No discreet masses, indicative of 
new brain metastases, were detected (Figure 1A).
The patient was admitted to the hospital where enzalutamide was discontinued. He was 
treated with dexamethasone. He was also treated with an antihypertensive regimen of 
hydralazine 25 mg three times daily and carvedilol, which was subsequently switched to 
amlodipine 10 mg daily, and hydralazine treatment was continued. His blood pressure 
returned to normal levels within three days. His neurological examination results and 
mentation improved steadily throughout his one-week hospitalization period, and he became 
fully oriented and conversational. He was discharged from the hospital on a regimen than 
included amlodipine, hydralazine and dexamethasone 2 mg twice daily. The dexamethasone 
was subsequently discontinued after one week. A follow-up brain MRI, performed five 
weeks after discharge, revealed significant improvement of abnormal T2/FLAIR signals 
bilaterally in the frontal, temporal, and occipital lobes, with only mildly abnormal signal still 
detected in the posterior lobe (Figure 1B). The MRI also revealed no midline shift or mass 
lesions and no evidence of intracranial hemorrhage, acute infarct, or extra-axial fluid 
collection. Four months after this episode of PRES, the patient was reported to be doing 
well, without recurrence of any neurologic symptoms. The patient had remained off 
enzalutamide and had not required any additional treatment for mCRPC other than 
continuing androgen deprivation therapy.
Discussion
The development of PRES has been correlated previously with hypertensive conditions 
ranging from severe acute hypertension to pre-eclampsia/eclampsia and hypertensive 
emergencies. Moreover, it has been associated with acute porphyria, Guillain-Barré 
syndrome, thrombotic thrombocytopenic purpura, solid organ transplant, and cancer.[2,3] In 
addition, PRES has been associated with the use of cyclosporine, erythropoietin, intravenous 
immunoglobulin, high-dose dexamethasone, and traditional cytotoxic chemotherapeutics 
(e.g., carboplatin, cisplatin, cyclophosphamide, cytarabine, doxorubicin, and gemcitabine).
[2,3,8-10] Recently, several case reports have emerged linking PRES to targeted anti-tumor 
agents that inhibit vascular endothelial growth factor and its receptors.[11]
The hypothesized etiologies of medication-induced PRES are poorly understood. One 
proposed model of pathogenesis centers on cerebral vascular autoregulation failure and 
endothelial dysfunction, which can often be secondary to medication-induced injury. Acute 
and severe cases of hypertension, resulting from injury to the vascular endothelium, may 
exceed cerebral vascular autoregulation. Sudden elevations in blood pressure, which exceed 
cerebral vascular autoregulation, cause pathological vasodilation of arterioles and result in 
blood-brain barrier dysfunction. Ultimately, blood-brain barrier dysfunction can lead to 
extravasation of fluids into the brain parenchyma.[1,4,12,13] A lack of adrenergic 
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innervation in the posterior cerebral circulation appears to render that area vulnerable to 
vasogenic edema.[12]
The mechanisms underlying the development of PRES as a result of exposure to 
enzalutamide are unknown. We propose that enzalutamide-induced inhibition of gamma-
aminobutyric acid A (GABAA)-gated chloride channels may explain the onset of PRES. 
One of the rare, yet serious, adverse events observed in the AFFIRM study was seizure that 
occurred in 5 (0.6%) out of 800 patients in the enzalutamide arm (while none of 399 patients 
in the placebo arm experienced seizure).[6] Animal studies suggest that lowered seizure 
threshold is a consequence of the ability of enzalutamide to cross the blood-brain barrier 
where it results in off-target inhibition of GABAA-gated chloride channels.[14] The 
AFFIRM study also revealed that the incidence of hypertension was twice as high in patients 
treated with enzalutamide than in those treated with placebo (6.6% versus 3.3%, 
respectively).[6] The GABAA inhibition in areas of the brain responsible for maintenance of 
sympathetic vasomotor tone (e.g., the paraventricular nucleus of the hypothalamus) has been 
shown to increase arterial blood pressure.[15] Another proposed alternate cause of PRES is 
related to cerebral vasospasm that leads to cerebral ischemia.[16] In preclinical models, the 
inhibition of GABAA receptors has been associated with increased regional cerebral blood 
flow and blood-brain barrier disruption in cerebral ischemia.[17] These data support the 
hypothesis that off-target inhibition of GABAA receptors by enzalutamide, especially in 
areas of the central nervous system (CNS) that are responsible for sympathetic tone, may 
lead to hypertension that exceeds cerebral vascular autoregulation and ultimately results in 
vasogenic edema. Furthermore, the blood-brain barrier disruption that occurs during this 
process may result in increased CNS concentrations of enzalutamide and, therefore, may 
accelerate the development of PRES. It is also possible that enzalutamide may induce PRES 
through an “off‐target” effect on molecules other than GABAA receptors in the CNS.
To our knowledge, this is the first reported case of enzalutamide-induced PRES. The 
patient’s clinical signs and symptoms and the MRI findings led to the diagnosis of PRES 
and the subsequent discontinuation of enzalutamide with a favorable clinical outcome. 
Prompt recognition and treatment of PRES are imperative because its clinical sequelae are 
not always reversible and can become both life-threatening and permanent.[18] Clinicians 
should be alert to the possibility of PRES, in addition to seizure, as an adverse event of 
enzalutamide that involves the CNS.
Acknowledgments
The authors would like to thank Dr. Amy Dorman for her expertise in reviewing and editing this case report. D.J.C. 
was supported by T32GM086330 from the National Institute of General Medicine Sciences (NIGMS).
Y.E.W. received research funding from Astellas and Janssen.
References
1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan 
LR. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334(8):494–500. 
[PubMed: 8559202] 
Crona and Whang Page 4













2. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior 
leukoencephalopathy syndrome. Arch Neurol. 2008; 65(2):205–210. [PubMed: 18268188] 
3. Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with 
anticancer drugs. Intern Med J. 2009; 39(12):826–834. [PubMed: 19220526] 
4. Tajima Y, Isonishi K, Kashiwaba T, Tashiro K. Two similar cases of encephalopathy, possibly a 
reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, 
SPECT and angiography. Intern Med. 1999; 38(1):54–58. [PubMed: 10052744] 
5. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, 
Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung 
ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced 
prostate cancer. Science. 2009; 324(5928):787–790. [PubMed: 19359544] 
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, 
Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, 
Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer 
after chemotherapy. N Engl J Med. 2012; 367(13):1187–11977. [PubMed: 22894553] 
7. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, 
Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, 
Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad 
F, Scher HI, Taplin ME, Venner PM, Tombal B. Enzalutamide in metastatic prostate cancer before 
chemotherapy. N Engl J Med. 2014; 371(5):424–4338. [PubMed: 24881730] 
8. Okeda R, Kawamoto T, Tanaka E, Shimizu H. An autopsy case of drug-induced diffuse cerebral 
axonopathic leukoencephalopathy: the pathogenesis in relation to reversible posterior 
leukoencephalopathy syndrome. Neuropathology. 2007; 27(4):364–370. [PubMed: 17899690] 
9. Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior 
leukoencephalopathy. Neurology. 1997; 49(3):686–689. [PubMed: 9305323] 
10. Irvin W, MacDonald G, Smith JK, Kim WY. Dexamethasone-induced posterior reversible 
encephalopathy syndrome. J Clin Oncol. 2007; 25(17):2484–2486. [PubMed: 17557962] 
11. Chelis, L.; Souftas, V.; Amarantidis, K.; Xenidis, N.; Chamalidou, E.; Dimopoulos, P.; 
Michailidis, P.; Christakidis, E.; Prassopoulos, P.; Kakolyris, S. 2012. Reversible posterior 
leukoencephalopathy syndrome induced by pazopanib
12. Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr 
Oncol Rep. 2008; 10(1):86–91. [PubMed: 18366965] 
13. Strandgaard S, Paulson OB. Cerebral autoregulation. Stroke. 1984; 15(3):413–416. [PubMed: 
6374982] 
14. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk 
JE, Balog A, Salvati ME, Attar RM, Gottardis MM. Drug safety is a barrier to the discovery and 
development of new androgen receptor antagonists. Prostate. 2011; 71(5):480–488. [PubMed: 
20878947] 
15. Li DP, Pan HL. Role of gamma-aminobutyric acid (GABA)A and GABAB receptors in 
paraventricular nucleus in control of sympathetic vasomotor tone in hypertension. J Pharmacol 
Exp Ther. 2007; 320(2):615–626. [PubMed: 17071818] 
16. Ito T, Sakai T, Inagawa S, Utsu M, Bun T. MR angiography of cerebral vasospasm in 
preeclampsia. AJNR Am J Neuroradiol. 1995; 16(6):1344–1346. [PubMed: 7677037] 
17. Chi OZ, Hunter C, Liu X, Chi Y, Weiss HR. Effects of GABA(A) receptor blockade on regional 
cerebral blood flow and blood-brain barrier disruption in focal cerebral ischemia. J Neurol Sci. 
2011; 301(1-2):66–70. [PubMed: 21094956] 
18. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a 
misnomer reviewed. Intern Med J. 2005; 35(2):83–90. [PubMed: 15705136] 
Crona and Whang Page 5














Brain MRI of the patient with PRES. (1A) The MRI at initial presentation revealed 
hyperintense signals on T2 sequences bilaterally in the occipital, parietal, temporal, and 
frontal lobes, which are indicative of diffuse vasogenic edema. Involvement of the corpus 
callosum, resulting in a 7-mm left-to-right midline shift, was also noted. (1B) After five 
weeks, a repeat MRI showed nearly complete resolution of abnormalities.
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